Article
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2011
Reinersman J Matthew, Johnson Melissa L, Riely Gregory J, Chitale Dhananjay A, Nicastri Anthony D, Soff Gerald A, Schwartz Ann G, Sima Camelia S, Ayalew Getinet, Lau Christopher, Zakowski Maureen F, Rusch Valerie W, Ladanyi Marc, Kris Mark G
Abstract excerpt
INTRODUCTION: The detection of mutations in the epidermal growth factor receptor (EGFR) gene, which predict sensitivity to treatment with EGFR tyrosine kinase inhibitors, represents a major advance in the treatment of lung adenocarcinoma. KRAS mutations confer resistance to EGFR-tyrosine kinase inhibitors. The prevalence of these mutations in African American patients has not been thoroughly investigated....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.